Weigh Judgment Before Giving Ramucirumab | Ramucirumab is Viable Choice After REACH-2 Results

Yung Lyou, MD, UC Irvine Health, talks about Weighing Judgment Before Giving Ramucirumab | Ramucirumab is Viable Choice After REACH-2 Results at MOASC 2018